UnitedHealthcare

Does UnitedHealthcare cover Zepbound?

Quick answer · Weight Loss

UnitedHealthcare covers it only when the plan's benefit includes it on Employer / Commercial Insurance and ACA Marketplace.

  • Employer / Commercial Insurance: Depends on your plan's benefit. This is an optional program for clients/businesses that have elected to cover weight loss products. Not available on plans without weight loss medication coverage (those plans use a separate Nonformulary Zepbound criteria policy).
  • ACA Marketplace: Depends on your plan's benefit. This is an optional program for clients/businesses that have elected to cover weight loss products. Not available on plans without weight loss medication coverage (those plans use a separate Nonformulary Zepbound criteria policy).

Last verified June 2, 2026. Policy effective March 1, 2026. Source: PA-Notification-Weight-Loss.pdf and PA-Non-Formulary-Zepbound.pdf. How we verify this data →

Check your card for your exact plan →

Zepbound for Weight Loss

What UnitedHealthcare requires, by plan type. Open this indication on its own page →

Employer / Commercial Insurance

Depends on your plan's benefit

This is an optional program for clients/businesses that have elected to cover weight loss products. Not available on plans without weight loss medication coverage (those plans use a separate Nonformulary Zepbound criteria policy).

No additional clinical requirements are listed beyond the diagnosis.

Policy note: The document explicitly states that medications for the purpose of weight loss are typically a benefit exclusion. This policy document is scoped only to the OSA indication for Zepbound. Weight loss as a standalone indication is not covered under this program.

Policy effective March 1, 2026 · verified June 2, 2026 · source: PA-Notification-Weight-Loss.pdf

ACA Marketplace

Depends on your plan's benefit

This is an optional program for clients/businesses that have elected to cover weight loss products. Not available on plans without weight loss medication coverage (those plans use a separate Nonformulary Zepbound criteria policy).

No additional clinical requirements are listed beyond the diagnosis.

Policy note: The document explicitly states that medications for the purpose of weight loss are typically a benefit exclusion. This policy document is scoped only to the OSA indication for Zepbound. Weight loss as a standalone indication is not covered under this program.

Policy effective March 1, 2026 · verified June 2, 2026 · source: PA-Notification-Weight-Loss.pdf

Zepbound for Osa

What UnitedHealthcare requires, by plan type. Open this indication on its own page →

Employer / Commercial Insurance

Covered with requirements

What you need to qualify

  • Age 18 and older
  • BMI of 30 or higher
  • A1C no higher than 6.5%
  • Prescribed by or in consultation with a specialist
  • Diagnosed obstructive sleep apnea (AHI of 15 or higher), with a documented trial of PAP therapy
  • Lab results confirming eligibility
  • Not being used to treat type 1 diabetes

Qualification pathways

You can qualify through any one of these.

Initial Authorization – Zepbound for OSA

All of:

  • Treatment requested for obstructive sleep apnea
  • Patient is 18 years of age or older
  • BMI >= 30 kg/m2 documented in medical records
  • Moderate-to-severe OSA evidenced by sleep study AND (AHI > 15 events/hour OR REI > 15 events/hour OR RDI > 15 events/hour)
  • At least one previous unsuccessful dietary effort to lose weight documented
  • Used in combination with a reduced calorie diet and increased physical activity
  • No diagnosis of diabetes AND HbA1c <= 6.5%
  • Provider attests patient counseled on appropriate positional therapy
  • Provider attests patient counseled on avoidance of alcohol and/or sedatives before bedtime
  • Prescriber attests no planned surgery for sleep apnea or obesity
  • Prescriber attests no diagnosis of predominant central or mixed sleep apnea (mixed/central apneas/hypopneas > 50% of all respiratory events)
  • Prescribed by or in consultation with a sleep specialist

Plus any one of:

  • Patient has continued symptoms of OSA despite PAP therapy adherence (>= 4 hours/night for >= 70% of nights)
  • Patient is not a candidate for PAP therapy (e.g., upper airway anatomic abnormalities)

Reauthorization – On therapy < 52 weeks

All of:

  • Patient has been on Zepbound for less than 52 weeks of consecutive therapy
  • Medical records confirm any decrease from baseline in AHI, RDI, or REI after initiating Zepbound
  • Weight loss >= 10% of baseline body weight
  • Used in combination with a reduced calorie diet and increased physical activity
  • No diagnosis of diabetes AND HbA1c <= 6.5%
  • Patient continues to require treatment for obstructive sleep apnea

Reauthorization – On therapy >= 52 weeks

All of:

  • Patient has been on Zepbound for >= 52 weeks of consecutive therapy
  • Medical records confirm >= 50% decrease from baseline in AHI, RDI, or REI after initiating Zepbound
  • Weight loss >= 10% of baseline body weight
  • Used in combination with a reduced calorie diet and increased physical activity
  • No diagnosis of diabetes AND HbA1c <= 6.5%
  • Patient continues to require treatment for obstructive sleep apnea

Documentation to bring

  • Medical records documenting BMI >= 30 kg/m2
  • Sleep study results confirming moderate-to-severe OSA
  • AHI > 15 events/hour OR REI > 15 events/hour OR RDI > 15 events/hour documented in sleep study
  • Documentation of at least one previous unsuccessful dietary effort to lose weight
  • Documentation of PAP therapy adherence failure (>= 4 hours/night for >= 70% of nights with continued OSA symptoms) OR documentation that patient is not a candidate for PAP therapy
  • HbA1c result confirming <= 6.5% and no diabetes diagnosis
  • Prescriber attestation that patient was counseled on positional therapy
  • Prescriber attestation that patient was counseled on avoidance of alcohol and/or sedatives before bedtime
  • Prescriber attestation that patient has no planned surgery for sleep apnea or obesity
  • Prescriber attestation that patient does not have predominant central or mixed sleep apnea
  • Documentation of sleep specialist prescribing or consultation
  • For reauthorization (< 52 weeks): Medical records showing any decrease from baseline in AHI, RDI, or REI
  • For reauthorization (>= 52 weeks): Medical records showing >= 50% decrease from baseline in AHI, RDI, or REI
  • For reauthorization: Documentation of >= 10% weight loss from baseline body weight

Quantity limits

  • all strengths — Supply limits may be in place (specific limits not defined in this document)

Approval and renewal

  • Initial approval: 6 months
  • To renew, the plan looks for at least 10% weight loss from the starting weight and Requires >= 10% weight loss from baseline AND improvement in AHI, RDI, or REI from baseline. For patients on therapy < 52 weeks: any decrease in AHI/RDI/REI; renewal is 6 months. For patients on therapy >= 52 weeks: >= 50% decrease in AHI/RDI/REI from baseline; renewal is 12 months. Diabetes exclusion (no diabetes diagnosis and HbA1c <= 6.5%) is re-verified at continuation. Make sure your starting weight and date are in the chart now — renewal is measured against it.

Not covered when

  • Diagnosis of diabetes
  • HbA1c > 6.5%
  • Planned surgery for sleep apnea or obesity
  • Predominant central or mixed sleep apnea (mixed/central apneas/hypopneas > 50% of all respiratory events)

Policy note: OSA severity is defined as AHI/REI/RDI > 15 events/hour (moderate-to-severe). PAP candidacy: patient must either have failed PAP therapy (defined as >= 4 hours/night for >= 70% of nights) with continued symptoms, or be documented as not a candidate for PAP. Reauthorization duration varies: 6 months if on therapy < 52 weeks; 12 months if on therapy >= 52 weeks. The 50% AHI/RDI/REI reduction threshold applies only at the >= 52-week renewal. The diabetes/HbA1c exclusion is re-verified at each reauthorization. Program number: 2025 P 1475-2. P&T Approval Dates: 3/2025, 12/2025. Effective Date: 3/1/2026.

Policy effective March 1, 2026 · verified June 2, 2026 · source: PA-Non-Formulary-Zepbound.pdf

ACA Marketplace

Covered with requirements

What you need to qualify

  • Age 18 and older
  • BMI of 30 or higher
  • A1C no higher than 6.5%
  • Prescribed by or in consultation with a specialist
  • Diagnosed obstructive sleep apnea (AHI of 15 or higher), with a documented trial of PAP therapy
  • Lab results confirming eligibility
  • Not being used to treat type 1 diabetes

Qualification pathways

You can qualify through any one of these.

Initial Authorization – Zepbound for OSA

All of:

  • Treatment requested for obstructive sleep apnea
  • Patient is 18 years of age or older
  • BMI >= 30 kg/m2 documented in medical records
  • Moderate-to-severe OSA evidenced by sleep study AND (AHI > 15 events/hour OR REI > 15 events/hour OR RDI > 15 events/hour)
  • At least one previous unsuccessful dietary effort to lose weight documented
  • Used in combination with a reduced calorie diet and increased physical activity
  • No diagnosis of diabetes AND HbA1c <= 6.5%
  • Provider attests patient counseled on appropriate positional therapy
  • Provider attests patient counseled on avoidance of alcohol and/or sedatives before bedtime
  • Prescriber attests no planned surgery for sleep apnea or obesity
  • Prescriber attests no diagnosis of predominant central or mixed sleep apnea (mixed/central apneas/hypopneas > 50% of all respiratory events)
  • Prescribed by or in consultation with a sleep specialist

Plus any one of:

  • Patient has continued symptoms of OSA despite PAP therapy adherence (>= 4 hours/night for >= 70% of nights)
  • Patient is not a candidate for PAP therapy (e.g., upper airway anatomic abnormalities)

Reauthorization – On therapy < 52 weeks

All of:

  • Patient has been on Zepbound for less than 52 weeks of consecutive therapy
  • Medical records confirm any decrease from baseline in AHI, RDI, or REI after initiating Zepbound
  • Weight loss >= 10% of baseline body weight
  • Used in combination with a reduced calorie diet and increased physical activity
  • No diagnosis of diabetes AND HbA1c <= 6.5%
  • Patient continues to require treatment for obstructive sleep apnea

Reauthorization – On therapy >= 52 weeks

All of:

  • Patient has been on Zepbound for >= 52 weeks of consecutive therapy
  • Medical records confirm >= 50% decrease from baseline in AHI, RDI, or REI after initiating Zepbound
  • Weight loss >= 10% of baseline body weight
  • Used in combination with a reduced calorie diet and increased physical activity
  • No diagnosis of diabetes AND HbA1c <= 6.5%
  • Patient continues to require treatment for obstructive sleep apnea

Documentation to bring

  • Medical records documenting BMI >= 30 kg/m2
  • Sleep study results confirming moderate-to-severe OSA
  • AHI > 15 events/hour OR REI > 15 events/hour OR RDI > 15 events/hour documented in sleep study
  • Documentation of at least one previous unsuccessful dietary effort to lose weight
  • Documentation of PAP therapy adherence failure (>= 4 hours/night for >= 70% of nights with continued OSA symptoms) OR documentation that patient is not a candidate for PAP therapy
  • HbA1c result confirming <= 6.5% and no diabetes diagnosis
  • Prescriber attestation that patient was counseled on positional therapy
  • Prescriber attestation that patient was counseled on avoidance of alcohol and/or sedatives before bedtime
  • Prescriber attestation that patient has no planned surgery for sleep apnea or obesity
  • Prescriber attestation that patient does not have predominant central or mixed sleep apnea
  • Documentation of sleep specialist prescribing or consultation
  • For reauthorization (< 52 weeks): Medical records showing any decrease from baseline in AHI, RDI, or REI
  • For reauthorization (>= 52 weeks): Medical records showing >= 50% decrease from baseline in AHI, RDI, or REI
  • For reauthorization: Documentation of >= 10% weight loss from baseline body weight

Quantity limits

  • all strengths — Supply limits may be in place (specific limits not defined in this document)

Approval and renewal

  • Initial approval: 6 months
  • To renew, the plan looks for at least 10% weight loss from the starting weight and Requires >= 10% weight loss from baseline AND improvement in AHI, RDI, or REI from baseline. For patients on therapy < 52 weeks: any decrease in AHI/RDI/REI; renewal is 6 months. For patients on therapy >= 52 weeks: >= 50% decrease in AHI/RDI/REI from baseline; renewal is 12 months. Diabetes exclusion (no diabetes diagnosis and HbA1c <= 6.5%) is re-verified at continuation. Make sure your starting weight and date are in the chart now — renewal is measured against it.

Not covered when

  • Diagnosis of diabetes
  • HbA1c > 6.5%
  • Planned surgery for sleep apnea or obesity
  • Predominant central or mixed sleep apnea (mixed/central apneas/hypopneas > 50% of all respiratory events)

Policy note: OSA severity is defined as AHI/REI/RDI > 15 events/hour (moderate-to-severe). PAP candidacy: patient must either have failed PAP therapy (defined as >= 4 hours/night for >= 70% of nights) with continued symptoms, or be documented as not a candidate for PAP. Reauthorization duration varies: 6 months if on therapy < 52 weeks; 12 months if on therapy >= 52 weeks. The 50% AHI/RDI/REI reduction threshold applies only at the >= 52-week renewal. The diabetes/HbA1c exclusion is re-verified at each reauthorization. Program number: 2025 P 1475-2. P&T Approval Dates: 3/2025, 12/2025. Effective Date: 3/1/2026.

Policy effective March 1, 2026 · verified June 2, 2026 · source: PA-Non-Formulary-Zepbound.pdf

Why Zepbound requests get denied by UnitedHealthcare

Based on what this policy asks for. Fix these before the first submission.

  1. Your specific plan doesn't include the weight loss benefit. Coverage here is conditional on the benefit design (often an optional employer add-on), so confirm it before submitting.
  2. Wrong brand for the diagnosis. Zepbound and Mounjaro are the same molecule with different approved uses; a request for Zepbound under a diagnosis that matches Mounjaro is routinely denied.
  3. BMI not documented in the chart notes (or documented without a baseline weight and date).
  4. Prescriber isn't the specialist the plan requires.
  5. Baseline weight wasn't recorded at the start, so the required weight loss can't be shown at renewal.

If weight loss isn't covered on your plan

UnitedHealthcare has separate Zepbound policies that don't depend on the weight loss benefit:

  • Osa — covered on Employer / Commercial Insurance and ACA Marketplace.

Zepbound is also sold directly by Eli Lilly without insurance through LillyDirect.

Frequently asked questions

Does UnitedHealthcare cover Zepbound?
UnitedHealthcare covers it only when the plan's benefit includes it on Employer / Commercial Insurance and ACA Marketplace.
How long does a Zepbound approval last with UnitedHealthcare?
Initial approvals last 6 months.
What does UnitedHealthcare require to renew Zepbound?
At least 10% weight loss from the starting weight and Requires >= 10% weight loss from baseline AND improvement in AHI, RDI, or REI from baseline. For patients on therapy < 52 weeks: any decrease in AHI/RDI/REI; renewal is 6 months. For patients on therapy >= 52 weeks: >= 50% decrease in AHI/RDI/REI from baseline; renewal is 12 months. Diabetes exclusion (no diabetes diagnosis and HbA1c <= 6.5%) is re-verified at continuation.
What if my plan excludes weight loss medications?
UnitedHealthcare has separate Zepbound policies for osa, which are covered on some plan types and don't depend on the weight-loss benefit. Zepbound is also available for cash through LillyDirect.
How current is this information?
This page reflects UnitedHealthcare's written policy as of March 1, 2026, last verified against the source document on June 2, 2026.

Other medications under UnitedHealthcare

Zepbound coverage under other plans

All insurance plans · All medications

This page summarizes UnitedHealthcare's written prior-authorization policy. It is not a guarantee of coverage; plans vary by employer and benefit design. Verify with your plan before relying on it.